Rare ALK Genetic Mutation Extends Cancer Survival
A new study from Yale University reveals that patients with the rare ALK mutation are living an average of four years, compared to typical patients that die of NSCLC within seven months. Most patients with non-small cell lung cancer (NSCLC) that has metastasized to the brain have a dire prognosis. But Yale researchers have identified […]
The post Rare ALK Genetic Mutation Extends Cancer Survival appeared first on SciTech Daily.
Read more »